Zhousheng Xiao, MD, PhD
Department of Nephrology- Medicine
University of Tennesse- Health Science Center
19S Manassas Street, CRB362; Memphis
TN 38103, USA
• 1987: MD (Medicine), Nanhua University, School of Medicine, Hunan, China
• 1992: MS (Cardiovascular Pharmacology), Central South University, Xiangya School of Medicine, Hunan, China
• 1995-1996: Post-Doctoral training (Pharmcogenetics), National Institute of Environmental Health Sciences, North Carolina, USA
• 1996-1999: Post-Doctoral training (bone biology), Duke University Medical Center, Neprology/ Medicine, North Carolina, USA
• 2003: PhD (Molecular Pharmacology and Bone Biology), Duke University Medical Center/Central South University, Xiangya School of Medicine, Hunan, China
POSITIONS AND EMPLOYMENT:
• (1987-1992): Teaching and Research Assistant, Pharmacology, Hunan Medical University
• (1992-1995): Assistant Professor, Pharmacology, Hunan Medical University
• (1995-1996): Postdoctoral, Human Metabolic Section, National Institute of Environmental Health Sciences
• (1996-1999): Post-doctoral, Nephrology/Medicine, Duke University Medical Center
• (1999-2001): Associate Professor, Pharmacology /Xiangya School of Medicine, Central South University
• (2001-2004): Research Assistant Professor, Nephrology/Medicine, Duke University Medical Center
• (2004-2009): Research Assistant Professor, the Kidney Institute/Internal Medicine, KU Medical Center
• (2009-2010): Research Associate Professor, the Kidney Institute/Internal Medicine, KU Medical Center
• (2009- present): Associate Professor, Nephrology/Medicine, Univ. of Tennessee Health Science Center
His major research interest is to investigate the role of ADPKD gene PKD1, PKD2, and primary cilia in osteoblasts and osteocytes in bone development and mechanosemnsingusing mouse genetic approaches and mechanical loading and unloading experiments in vivo and in vitro. Dr. Xiao is also working the role of Fgfr1 signaling in regulating FGF23 expression in XLH patients and Hyp mice. He had been working on the molecular pharmacology of phytoestrogen in osteoblastic differentiation. He used to be a researcher in Pharmcogenetics and cardiovascular pharmacology.
• (1995-2001): A member of the Chinese Pharmacological society
• (1999-2001): Director/Molecular Pharmacology, Xiangya School of Medicine, Central South University
• (2002- present): A member of the American Society for Bone and Mineral Research
HONORS AND AWARDS:
• 1996 Young Investigator Award from the Nature Science Foundation Commission of Hunan
• 1999 Third Prize of Science and Technology Progress from the State Education Commission of China
• 2000 Excellent Young Teacher and Researcher from the Education Commission of China
• 2001 First Prize of Science and Technology Progress Award from the University Commission of China
• 2003 Young Investigator Award of 25th the American Society for Bone and Mineral Research, USA
1. Dai J, Li Y, Zhou H, Chen J, Chen M, Xiao ZS. Genistein promotion of osteogenic differentiation through BMP2/SMAD5/RUNX2 signaling. Int J Biol Sci. 2013; 9(10): 1089-1098. doi: 10.7150/ijbs.7367
2. Qiu N, Xiao ZS, Cao L, David V, Quarles LD. Conditional Disruption of Pkd1 in Mesenchymal Lineage Results in Osteopenia and Polycystic Kidney Disease. PLoS One. 2012; 7(9): e46038. doi: 10.1371/journal.pone.0046038
3. Qiu N, Xiao ZS, Cao L, et al. Disruption of Kif3a in osteoblasts results in defective bone formation and osteopenia. Journal of Cell Science. 2012; 125(8): 1945-1957. doi: 10.1242/jcs.095893
4. Qiu N, Zhou H, Xiao ZS. Down regulation of PKD1 by shRNA results in defective osteogenic differentiation via cAMP/PKA pathway in human MG-63 cells. J Cell Biochem. 2011; 113(3): 967-976. doi: 10.1002/jcb.23426
5. Xiao ZS, Dallas M, Qiu N, et al. Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. FASEB J. 2011; 25(7): 2418-2432. doi: 10.1096/fj.10-180299
6. He N, Xiao ZS, Yin T, Stubbs J, Li L, Quarles LD. Inducible expression of Runx2 results in multiorgan abnormalities in mice. J Cell Biochem. 2011; 112(2): 653-665. doi: 10.1002/jcb.22968
7. Qiu N, Cao L, David V, Quarles LD, Xiao ZS. Kif3a deficiency reverses the skeletal abnormalities in Pkd1 deficient mice by restoring the balance between osteogenesis and adipogenesis. PLoSOne. 2010; 5(12): e15240. doi: 10.1371/journal.pone.0015240
8. Xiao ZS and Quarles LD. Role of the Polycytins-Primary Cilia Complex in Bone Development and Mechanosensing. Ann N Y Acad Sci. 2010; 1192(1): 410-421. doi: 10.1111/j.1749-6632.2009.05239.x
9. Xiao ZS, Zhang SQ, Cao L, Qiu N, David V, Quarles LD. Conditional Disruption of Pkd1 in Osteoblasts Results in Osteopenia due to Direct Impairment of Bone. J Biol Chem. 2010; 285(2): 1177-1187. doi: 10.1074/jbc.M109.050906
10. Zhang SQ, Xiao ZS, Luo JM, He N, Mahlios J, Quarles LD. Dose-dependent effects of Runx2 on bone development. J Bone Miner Res. 2009; 24(11): 1889-1904. doi: 10.1359/jbmr.090502
11. Liu S, Tang W, Fang J, et al. Novel Regulators of Fgf23 Expression and Mineralization in Hyp Bone. Mol Endocrinol. 2009; 23(9): 1505-1518. doi: 10.1210/me.2009-0085
12. Li YL, Pan W, Xu WF, et al. RUNX2 mutations in Chinese patients with cleidocranial dysplasia. Mutagenesis. 2009; 24(5): 425-431. doi: 10.1111/eos.12048
13. Xiao ZS, Zhang S, Magenheimer BS, Luo J, Quarles LD. Polycystin-1 regulates skeletogenesis through stimulation of the osteoblast-specific transcription factor Runx2-II. J Biol Chem. 2008; 283(18): 12624-12634. doi: 10.1074/jbc.M710407200
14. Xiao ZS, Zhang S, Mahlios J, et al. Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression. J Biol Chem. 2006; 281(41): 30884-30895.
15. Li YL, Zhang W, Guo D, Zhou G, Zhou HH, Xiao ZS. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clinica Chimica Acta. 2008; 391(1-2): 60-67. doi: 10.1016/j.cca.2008.02.003
16. Huang L, Qiu N, Xiao ZS, et al. Nitroglycerin enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via nitric oxide pathway. Acta Pharmacol Sin. 2008; 29(5): 580-586. doi: 10.1111/j.1745-7254.2008.00778.x
17. Liao QC, Li YL, Qin YF, et al. Inhibition of adipocyte differentiation by phytoestrogen genistein through a potential downregulation of extracellular signal-regulated kinase 1/2 activity. J Cell Biochem. 2008; 104(5): 1853-1864. doi: 10.1002/jcb.21753
18. Li YL, Quarles LD, Zhou HH, Xiao ZS. RNA interference and its application in bone-related diseases. Biochem Biophys Res Commun. 2007; 361(4): 817-821.
19. Liao QC, Xiao ZS, Qin YF, Zhou HH. Genistein stimulates osteoblastic differentiation via p38 MAPK-Cbfa1 pathway in bone marrow culture. Acta Pharmacol Sin. 2007; 28(10): 1597-1602.
20. Li YL, Xiao ZS. Advances in Runx2 regulation and its isoforms. Med Hypotheses. 2007; 68(1): 169-175.
21. Dai ZJ, Li YL, Quarles LD, et al. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine. 2007; 14: 806-814.
22. Song LH, Pan W, Yu YH, Quarles LD, Zhou HH, Xiao ZS. Resveratrol prevents CsA inhibition of proliferation and osteoblastic differentiation of mouse bone marrow-derived mesenchymal stem cells through an ER/NO/cGMP pathway. ToxicolIn Vitro. 2006; 20(6): 915-922.
23. Pan W, Quarles LD, Xiao ZS, et al. Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture. J Cell Biochem. 2005; 94(2): 307-316.
24. Liu S, Brown TA, Xiao ZS, et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol. 2005; 16(6): 1645-1653.
25. Xiao ZS, Awad HA, Liu S, et al. Selective Runx2-II deficiency leads to low-turnover osteopenia in adult mice. Dev Biol. 2005; 283: 345-356.
26. Xiao ZS, Hjelmeland AB, Quarles LD. Selective deficiency of the bone-related Runx2-II unexpectedly preserves osteoblast-mediated skeletogenesis. J Biol Chem. 2004; 279(19): 20307-20313. doi: 10.1074/jbc.M401109200
27. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003; 278(39): 37419-37426. doi: 10.1074/jbc.M304544200
28. Guo R, Rowe PS, Liu S, Simpson LG, Xiao ZS, Darryl Quarles LD. Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun. 2002; 297(1): 38-45.
29. Xiao ZS, Simpson LG, Quarles LD. IRES-dependent translational control of Cbfa1/Runx2 expression. J Cell Biochem. 2002; 99: 1-13.
30. He N, Yan FX, Huang SL, et al. CYP 2C19 genotype and S-mephenytoin 4-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol. 2002; 58: 15-18. doi: 10.1007/s00228-002-0425-x
31. Xiao ZS, Quarles LD, Chen QQ, et al. Effect of asymmetric dimethylarginine on osteoblastic differentiation. Kidney Int. 2001; 60: 1699-1704. doi: 10.1046/j.1523-1755.2001.00011.x
32. Xiao ZS, Liu SG, Hinson TK, Quarles LD. Characterization of the upstream mouse Cbfa1/Runx2 Promoter. J Cell Biochem. 2001; 82: 647-659. doi: 10.1002/jcb.1192
33. Xiao ZS, Hinson TK, Quarles LD. Cbfa1 isoform overexpression upregulatesosteocalcin gene expression in non-osteoblastic and pre-osteoblastic cells. J Cell Biochem. 1999; 74(4): 596-605. doi: 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.3.CO;2-6
34. Xie HG, Stein CM, Kim RB, et al. Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics. 1999;9: 511-516.
35. Xiao ZS, Crenshaw M, Guo R, Nesbitt T, Quarles LD. Intrinisic mineralization defect in hyp mouse osteoblasts. Am J Physiol. 1998; 275: E700-E708.
36. Nesbitt, T, Fujiwara, I, Thomas, R, Xiao ZS, Quarles LD, Drezner MK. Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity: evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia. J Bone Min Res. 1999;14(12): 2027-2035. doi: 10.1359/jbmr.19188.8.131.527
37. Xiao ZS, Thomas R, Hinson TK, Quarles LD. Genomic structure and isoform expression of mouse, rat and human Cbfa1/Osf2 transcription factor. Gene. 1998; 214: 187-197. doi: 10.1016/S0378-1119(98)00227-3
38. Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exper Ther. 1997; 281: 604-609.
39. Xie HG, Huang SL, Xu ZH, Xiao ZS, Zhou HH. Evidence for the effect of gender on activity of (S)-mephenytoin 4-hydroxylase (CYP2C19) in Chinese population. Pharmacogenetics. 1997; 7: 115-119.
40. Xiao ZS, Xie HG, He N, et al. The effect of gene dose on the activity of S-mephenytoin hydroxylase. Natl Med J China. 1996; 76(5): 389-390.
41. Xiao ZS, Li YJ, Deng HW. Ischemic preconditioning mediated by calcitonin generelated peptide in isolated rat hearts. Acta Pharmacol Sin. 1996; 17: 445-448.
42. Xiao ZS, Fang YX, Chen X. Effects of sodium salicylate on ischemia and reperfusion injury in isolated rat hearts. Chinese journal of pharmacology and toxicology. 1994; 8(3): 187-190.
43. Li YJ, Xiao ZS, Peng CF, Deng HW. Calcitonin gene-related peptide-induced preconditioning protects against ischemia-reperfusion injury in isolated rat hearts. Eur J Pharmacol. 1996; 311: 163-167. doi: 10.1016/0014-2999(96)00426-8
44. Nayani SS, Xiao Z. Recent advances in fibroblast growth factor-23 functions. Nephrol Open J. 2016; 1(3): 51-58. doi: 10.17140/NPOJ-1-110